Literature DB >> 3049656

Comparison of immunofluorescence, enzyme immunoassay, and Western blot (immunoblot) methods for detection of antibody to human T-cell leukemia virus type I.

D Gallo1, M N Hoffman, C K Cossen, J L Diggs, J W Hurst, L M Penning.   

Abstract

A total of 3,349 serum samples were screened by the immunofluorescence (IF) method for antibody to human T-cell leukemia virus type I (HTLV-I). Only 9 of 2,409 specimens from selected individuals, blood bank donors, patients with encephalitis-meningitis, and human immunodeficiency virus antibody-positive homosexual or bisexual men were reactive by IF. In addition, 940 serum samples from intravenous drug abusers were tested by IF and also by an HTLV-I enzyme immunoassay (EIA) method. Of these, 222 (24%) were positive for both HTLV-I and HTLV-II antigens by IF, and 191 of these 222 were also reactive in the HTLV-I EIA. Of the 31 IF-positive, EIA-negative serum samples, 20 exhibited optical density readings greater than or equal to 70% of the positive cutoff in the EIA, and 29 samples reacted with 1 or more bands in the Western blot (immunoblot) test. An additional 10 specimens that were EIA negative reacted only with HTLV-I by IF. Differences in staining morphology and in reactions on HTLV-I and HTLV-II antigens before and after absorption of the serum specimens with HTLV-I and HTLV-II-infected cell pellets revealed six distinct serological patterns by IF. These results indicate that infections by HTLV-I or by another closely related retrovirus(es) occur in California. Further studies utilizing statistically valid sampling methods are needed to estimate true prevalence rates among various groups. IF and Western blot tests should supplement the EIA method to maximize sensitivity and specificity of test procedures.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3049656      PMCID: PMC266647          DOI: 10.1128/jcm.26.8.1487-1491.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  HTLV-I and HTLV-III antibodies and tropical spastic paraparesis.

Authors:  P Rodgers-Johnson; D C Gajdusek; O S Morgan; V Zaninovic; P S Sarin; D S Graham
Journal:  Lancet       Date:  1985-11-30       Impact factor: 79.321

2.  Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells.

Authors:  I Miyoshi; I Kubonishi; S Yoshimoto; T Akagi; Y Ohtsuki; Y Shiraishi; K Nagata; Y Hinuma
Journal:  Nature       Date:  1981-12-24       Impact factor: 49.962

3.  Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region.

Authors:  M Robert-Guroff; S H Weiss; J A Giron; A M Jennings; H M Ginzburg; I B Margolis; W A Blattner; R C Gallo
Journal:  JAMA       Date:  1986-06-13       Impact factor: 56.272

4.  Comparison of detection of antibody to the acquired immune deficiency syndrome virus by enzyme immunoassay, immunofluorescence, and Western blot methods.

Authors:  D Gallo; J L Diggs; G R Shell; P J Dailey; M N Hoffman; J L Riggs
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

5.  Human T-cell leukemia virus (HTLV-I) antibodies in Africa.

Authors:  W Saxinger; W A Blattner; P H Levine; J Clark; R Biggar; M Hoh; J Moghissi; P Jacobs; L Wilson; R Jacobson
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

6.  Antibodies against three purified proteins of the human type C retrovirus, human T-cell leukemia-lymphoma virus, in adult T-cell leukemia-lymphoma patients and healthy Blacks from the Caribbean.

Authors:  J Schüpbach; V S Kalyanaraman; M G Sarngadharan; W A Blattner; R C Gallo
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

7.  The human type-C retrovirus, HTLV, in Blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma.

Authors:  W A Blattner; V S Kalyanaraman; M Robert-Guroff; T A Lister; D A Galton; P S Sarin; M H Crawford; D Catovsky; M Greaves; R C Gallo
Journal:  Int J Cancer       Date:  1982-09-15       Impact factor: 7.396

8.  A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia.

Authors:  V S Kalyanaraman; M G Sarngadharan; M Robert-Guroff; I Miyoshi; D Golde; R C Gallo
Journal:  Science       Date:  1982-11-05       Impact factor: 47.728

9.  Studies of human retroviruses in relation to adult T-cell leukaemia, acquired immune deficiency syndrome, and multiple sclerosis.

Authors:  A Karpas; K Malik; J Lida
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

  10 in total
  11 in total

1.  Comparison of six commercial human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassay kits for detection of antibody to HTLV-I and -II.

Authors:  C Cossen; S Hagens; R Fukuchi; B Forghani; D Gallo; M Ascher
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

2.  Detection and differentiation of antibodies to human T-cell lymphotropic virus types I and II by the immunofluorescence method.

Authors:  D Gallo; L M Penning; C V Hanson
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

3.  Comparison of Western immunoblot antigens and interpretive criteria for detection of antibody to human T-lymphotropic virus types I and II.

Authors:  D Gallo; J L Diggs; C V Hanson
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

4.  Serological evaluation of Escherichia coli-expressed human T-cell leukemia virus type I env, gag p24, and tax proteins.

Authors:  S R Coates; A J Harris; D L Parkes; C M Smith; H L Liu; R W Akita; M M Ferrer; E K Sampson; J W Brandis; M X Sliwkowski
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

5.  Comparison of immunofluorescence, particle agglutination, and enzyme immunoassays for detection of human T-cell leukemia virus type I antibody in African sera.

Authors:  M Verdier; F Denis; G Leonard; A Sangare; S Patillaud; M Prince-David; M Essex
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

6.  Sensitivities of radioimmunoprecipitation assay and PCR for detection of human T-lymphotropic type II infection.

Authors:  D Gallo; L M Penning; J L Diggs; C V Hanson
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

7.  HIV-1, HIV-2, HTLV-I/II and STD among female prostitutes in Buenos Aires, Argentina.

Authors:  I Zapiola; S Salomone; A Alvarez; M C Scolastico; R A Koessel; J Lemus; C Wainstein; G Muchinik
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

8.  Evaluation of two commercial human T-cell lymphotropic virus western blot (immunoblot) kits with problem specimens.

Authors:  D Gallo; J L Diggs; C V Hanson
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

Review 9.  Differential diagnosis of human retrovirus infections in the laboratory.

Authors:  B P Griffith
Journal:  Yale J Biol Med       Date:  1989 Mar-Apr

Review 10.  Nanotechnology based strategies for HIV-1 and HTLV-1 retroviruses gene detection.

Authors:  Sayed-Hamidreza Mozhgani; Hanie Ahmadzade Kermani; Mehdi Norouzi; Mohsen Arabi; Saber Soltani
Journal:  Heliyon       Date:  2020-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.